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Endothelin (ET) peptides perform several physiological, vascu-
lar,andnonvascularfunctionsandarewidelydistributedinanum-
ber of tissues. They are altered in several disease processes includ-
ing diabetes. Alteration of ETs have been demonstrated in organs
of chronic diabetic complications in both experimental and clini-
cal studies. The majority of the effects of ET alteration in diabetes
are due to altered vascular function. Furthermore, ET antagonists
have been shown to prevent structural and functional changes in-
duced by diabetes in animal models. This review discusses the con-
tribution of ETs in the pathogenesis and the potential role of ET
antagonism in the treatment of chronic diabetic complications.
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Globally, diabetes is considered as a major threat to human
healthinthe21stcentury[1].Itisestimatedthatabout6%ofthe
NorthAmericanpopulationsuffersfromdiabetesmellitus[2,3].
Chronicdiabeticcomplicationsconstituteagroupofdiseasesre-
sponsibleforsubstantialmorbidityandmortality,andprevention
ofsuchcomplicationsisakeyissueinthemanagementofthedi-
abetesepidemic[1–4].Therapeuticmodalitiesfordiabeteshave
evolved a great deal. However, most people with this disorder
go on to develop complications leading to damage to various
body tissues. These complications include diabetic retinopathy,
nephropathy, neuropathy, cardiomyopathy, and macroangio-
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pathic complications such as atherosclerosis. The macrovas-
cular complications are not diabetes speciﬁc but are more
pronounced in diabetes. Diabetic complications arise primarily
because of hyperglycemia-induced metabolic changes leading
to changes in the structural and functional properties of macro-
molecules[5,6].Recentadvanceshaveidentiﬁedsecondaryfac-
tors that play key roles in the development and progression of
these complications. Some of the factors that participate in the
pathogenesis of diabetic complications include protein kinase
C (PKC) activation, nonenzymatic glycation, oxidative stress,
and alterations in growth factor and vasoactive factor expres-
sion. Several of these factors may subsequently lead to further
endothelin (ET) activation in diabetic subjects.
ETs AND THEIR RECEPTORS
ETs are potent vasoactive factors. These 21–amino acid
peptides cause vasodilation at lower concentrations and sus-
tainedcontractionathighconcentrations.ThreeisoformsofETs
exist: ET-1, ET-2, and ET-3 [7]. These peptides are encoded by
3 distinct genes. The encoded precursor proteins are spliced by
endopeptidases to produce big ETs. A group of proteins called
endothelin-converting enzymes (ECEs) then convert these big
ETs into mature ET peptides. Two ECEs have been cloned,
ECE1 and ECE2 [8, 9]. ECE1 has 4 isoforms (ECE1a–d) and is
mainly located on the cell surface, with the exception of ECE1b
[10–13]. ECE1b and ECE2 have been localized intracellularly
in close proximity to the Golgi network [12].
ETs act on speciﬁc receptors (ETA and ETB). ETA has high
afﬁnityforET-1andET-2butlowafﬁnityforET-3andisprimar-
ily involved in vasoconstriction [14]. ETB, on the other hand, is
equallyresponsivetoallisoformsandisinvolvedinvasodilation
by increasing nitric oxide (NO) generation by endothelial cells
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[15]. In some cells, ET receptors are coupled to voltage-gated
calcium channels, while in others to the activation of phospho-
lipase C. The vasoconstrictive property is due to calcium in-
crease in smooth muscle cells, which results from activation of
phospholipase C and production of diacylglycerol and inositol
trisphosphate. The differential responsiveness of ETA receptors
to various agonists and antagonists suggests that subtypes of
the receptor exist [16–24]. However, no conclusive study has
favored the postulate. Radioligand binding studies conducted in
the late 1990s have contradicted the existence of ETA subtypes
[25, 26]. This suggests that ETA responsiveness to various stim-
ulators and inhibitors depends on the intrinsic properties of the
ligands. However, similar studies on potencies of ET antago-
nists on ETB receptor have suggested the existence of 2 receptor
subtypes, ETB1 and ETB2 [23, 24, 27, 28].
Hypoxia and ischemia are 2 important conditions that may
lead to ET up-regulation [29, 30]. However, at the molecular
FIGURE 1
Vasoactivity of endothelins (ETs). Various stimulators and inhibitors regulate transcription of ETs. The precursor peptides are
acted upon by endopeptidases and ET-converting enzymes to produce mature ET peptides. These ET peptides act on
G-protein–coupled receptors on endothelial and smooth muscle cells. Interaction of ET with ETB receptor on endothelial cells
leads to increased nitric oxide synthase expression and nitric oxide production. Nitric oxide has an inhibitory effect on ET
transcription. In addition, nitric oxide can increase soluble guanylate cyclase activity in smooth muscle cells. Activated guanylate
cyclase leads to increases in cGMP and a reduction in intracellular CaCC, resulting in vasodilation. ETs can also activate
phospholipase C (PLC) in smooth muscle cells via G-protein–coupled ETA or ETB receptors. Activation of PLC increases
hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) to release 2 second messengers, 1,2-diacylglycerol (DAG) and
1,4,5-inositol trisphosphate (IP3). DAG activates PKC and IP3 increases intracellular calcium. Elevated intracellular calcium
leads to myosin kinase phosphorylation and results in contraction. ETs can also regulate the activity of NaC/HC exchanger
and NaC,KC-ATPase on smooth muscle cell surface.
level,severalimportantintracellularmoleculesmayregulateET
mRNAexpressioninhealthanddisease[31–38].Majorityofthe
ET-related effects in the target organs of diabetic complications
may be mediated via its effects on the vasculature. Nonvascular
effects of ETs in the pathogenesis of diabetic complications, al-
thoughpotentiallyofimportance,havenotbeenstudiedindetail.
AdiagrammaticrepresentationoftheregulationofET-1mRNA
expressionandthemechanismsofETactionsonendothelialand
smooth muscle cells are outlined in Figure 1.
MECHANISMS OF ET ALTERATION
IN DIABETES
Several biochemical abnormalities secondary to hyper-
glycemia may lead to ET alteration in the target organs of
diabetic complications. The metabolic pathways leading to ET
activation include PKC activation, altered redox state, as well asALTERED ENDOTHELINS IN CHRONIC DIABETES 219
alteration of other vasoactive factors. We will brieﬂy discuss the
mechanismsofthesefactorsleadingtoETalterationindiabetes.
PKC Activation
PKC activation assumes a central role in hyperglycemia-
induced vascular disorders. High glucose concentrations can
induce the production of diacylglycerol and activation of PKC
[39–41]. PKC activation has been implicated in hyperglycemia-
induced vascular permeability and ﬂow changes, expansion of
extracellular matrix, and in the production of various growth
factors and cytokines [42–48]. One isoform in particular,
PKC¯, has been shown to be activated in all tissues affected
by chronic diabetes. PKC activation also leads to activation of
phospholipase A and production of arachidonic acid metabo-
lites. Furthermore, PKC activation can result in the impairment
ofNaC,KC-ATPaseandendothelialdamage[49,50].Studieson
PKC activation and ETs have suggested an interaction between
the 2 factors. We and others have demonstrated that endothelial
cellsexposedtoET-1orphorbol12-myristate13-acetate(PMA)
(a potent PKC activator) show similar permeability changes as
seen in hyperglycemia [42]. These changes are prevented when
cellsaretreatedwithETreceptorantagonistsorPKCinhibitors.
Furthermore, structural changes, such as F-actin microﬁlament
assembly secondary to glucose, ET-1, or PKC activation, are
also ameliorated by respective inhibition [42].
Polyol Pathway and Redox State
Early experiments aimed toward elucidating the mechanis-
tic basis of chronic diabetic complications focused on sorbitol
accumulation and accompanying cellular damage. Glucose is
converted to sorbitol via augmented polyol pathway. The en-
zyme responsible, aldose reductase, has been shown to be up-
regulated in all tissues affected by chronic diabetic complica-
tions [43, 51]. Increased intracellular concentrations of sorbitol
can cause osmotic changes, cell swelling, and abnormalities in
myoinositolmetabolismandcanleadtoimpairmentofNaC,KC-
ATPase. Aldose reductase inhibition has been shown to prevent
hyperglycemia-induced damage in diabetic retinopathy, neu-
ropathy, and nephropathy to some extent [52, 53]. The mecha-
nismbywhichaldosereductaseinhibitionpreventsdevelopment
ofvascularcomplicationsisnotfullyunderstood.Aldosereduc-
tase requires NADPH for the conversion of glucose to sorbitol.
Sorbitol is then converted to fructose by sorbitol dehydroge-
nase. The latter step requires NADC reduction for the enzy-
matic conversion. This suggests that an imbalance in the redox
state, that is, altered NADH:NAD and NADPH:NADP might
cause endothelial dysfunction secondary to increased aldose re-
ductase activity [43, 51, 54]. Interestingly, depleted NADPH
may also lead to reduced NO production as the enzymatic reac-
tion of NO synthesis requires NADPH, which may result in ET
up-regulation.
Nonenzymatic Glycation
Nonenzymatic glycation and generation of advanced gly-
cated end (AGE) products has been demonstrated as an im-
portant factor in the pathogenesis of chronic diabetic compli-
cations [43, 55–57]. Glucose, fructose, and the product of the
pentose phosphate pathway may participate in nonenzymatic
glycation [56–58]. AGEs and the reactive intermediates may
have widespread biological actions [55–59]. AGEs may further
increase oxidative stress and endothelial damage [55–59]. Ex-
ogenousadministrationofsuperoxidedismutasehasbeenshown
to reduce hyperglycemia-induced endothelial permeability and
accompanyingvasculardysfunction[59–62].Inaddition,AGEs
can form cross-links with collagen in the extracellular matrix,
reduce arterial compliance, and alter gene expression of several
important intracellular molecules [55–57]. Aminoguanidine, a
speciﬁc inhibitor of nonenzymatic glycation, has been shown to
inhibit the development of retinopathy in diabetic dogs [63–65].
Several receptors for AGE have been identiﬁed. Both AGEs
andtheirreceptorshavebeenlocalizedtothetargetorgansofdia-
beticcomplications[55–57].Thesereceptorsarefoundonmany
cells,includingendothelialandsmoothmusclecells.Interaction
of AGEs with these receptors leads to mitogen activated protein
kinase (MAPK) kinase signaling and nuclear factor kappa B
(NF-·B) activation. AGE-mediated NF-·B activation has been
shown to increase ET-1 expression [66]. Activation of NF-·B
secondary to nonenzymatic glycation has also been linked to
reduced NO, which would positively affect ET expression [67].
Nitric Oxide and Oxidative Stress
NO is a potent vasodilator formed from L-arginine by NO
synthase (NOS) [68]. This enzyme has 2 major isoforms,
calcium-calmodulin–dependent endothelial NOS (also called
eNOS) and calcium-calmodulin–independent inducible NOS
(alsocallediNOS).eNOSisexpressedconstitutivelyinendothe-
lial cells and some other cells, whereas iNOS is only expressed
when cells are stimulated by various factors [69–71]. NO re-
leased from endothelial cells acts on smooth muscle cells to
increase intracellular cGMP and cAMP. The result of this in-
crease in cGMP and cAMP is decreased calcium, probably via
efﬂux, and dephosphorylation of myosin light chains [72]. En-
dothelialdysfunctionischaracterizedbytheimbalancebetween
contracting and relaxing factors. The mechanism of glucose-
mediated endothelial dysfunction is not fully understood, but
evidence indicates increased ET production and impaired NO
may contribute signiﬁcantly in this abnormality [73–77]. There
isanegativeinteractionbetweenNOandET,therebyareduction
in NO leads to increased ET expression.220 S. CHAKRABARTI ET AL.
Generation of free radicals due to glucose autoxidation
may also damage proteins [78]. Various lipoxygenase enzymes
activated in hyperglycemia may interact with NO, forming per-
oxynitrateandhydroxylradicals[79,80].Augmentedmitochon-
drialproductionofsuperoxideionssecondarytohyperglycemia
has recently been proposed as a unifying initiating mechanism
[81,82].Increasedsuperoxideionsmayinhibittheglycolyticen-
zyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
hence excess glucose is deviated to avenues of metabolism,
leading to the activation of PKC, augmented polyol pathway,
generation of methyl glyoxal, and AGE formation, as well as
increased ﬂux through hexosamine pathway [81, 82]. In several
cell types, overexpression of superoxide dismutase (SOD) has
been shown to prevent speciﬁc glucose-induced abnormalities
[81, 83, 84]. Furthermore, in transgenic mice overexpressing
MnSOD, diabetes-induced lesions were prevented [81].
Other Factors
Increased vascular permeability is one of the characteristic
featuresofendothelialdysfunction.Thispermeabilityalteration
is due to the expression of vascular endothelial growth factor
(VEGF), which has been demonstrated in diabetes [85–90].
VEGF is a member of a large family of proteins, with 5 iso-
formsgeneratedbyalternativesplicing[91,92].Themechanism
by which VEGF carries out the permeability and proliferative
changesseemstoinvolvePKC[89].Variousvasoactivepeptides
can also induce VEGF production [47]. VEGF activates 1,4,5-
inositol triphosphate (PI3) kinase and phospholipase C gamma
(PLC°). Activation of PLC° increases 1,2-diacylglycerol
(DAG) and activates PKC® and PCK¯. Oral administration of
PKC inhibitors, speciﬁcally PKC¯, prevents VEGF-mediated
retinal permeability and endothelial proliferation [89]. ETs are
probablyalsoimportantinmediatingglucose-inducedincreased
permeability [42]. We and others have demonstrated that VEGF
may further increase ET expression in endothelial cells of the
diabetic rat retina [42].
A large number of studies indicate the role of angiotensin
in the development of diabetic micro- and macrovasculopathy.
Angiotensin II has mitogenic effects on smooth muscle cells
and can lead to increased extracellular matrix (ECM) protein
synthesis by these cells [93]. Recent reports indicate that there
might be an interaction between the renin-angiotensin pathway
and the ET system [94]. In vitro studies have demonstrated an
angiotensin II–mediated increase in ET expression [95].
PATHOPHYSIOLOGICAL ROLE OF ETs
IN DIABETES
ET alteration, in diabetes, may lead to several functional and
structural effects that are important in the development of sev-
eral chronic complications. Both glucose and insulin, poten-
FIGURE 2
Mechanism and consequences of ET alteration in diabetes. A
schematic outline of various hyperglycemia-induced pathways
leading to increases in ET levels (upper half of ﬁgure). Some
of the major effects of increased ET levels are also presented
(shown in italics; lower half of the ﬁgure).
tially of importance in insulin resistance, are ET-1 up-regulators
[95, 96]. We and others have demonstrated that in endothelial
cells and in several target organs of diabetic complications, ETs
are up-regulated [97–104]. Studies in human diabetes with re-
spect to serum ET levels have shown a widespread variation,
ranging from increased to unchanged to decreased [105–114].
Several factors may be responsible for such discrepancy. How-
ever,asETsactasautocrineandparacrinefactors,plasmalevels
may not be a good indicator of their biological activity [115,
116]. Increased ETs may lead to increased vascular permeabil-
ity and altered of blood ﬂow [42]. In addition, increased ET lev-
els may contribute greatly to hypertension in diabetics. Studies
conducted to determine the role of ETs in essential hyperten-
sion have shown inconsistent data. However, there does seem to
be a positive association between the 2 factors [117]. ETs may
also lead to increased ECM protein production in diabetes via
activation of transcription factors NF-·B and activated protein
(AP-1) [118, 119]. Furthermore, they may potentially play im-
portant roles in angiogenesis [120–122]. Some of the major ef-
fectsofETalterationindiabetesareoutlinedinFigure2.Wewill
discusstheroleofETsinspeciﬁcdiabeticcomplicationsbelow.
DIABETIC RETINOPATHY
Diabetes is the most important systemic disease causing
blindness [123, 124]. Diabetic retinopathy is classiﬁed in var-
ious progressive stages, namely, nonproliferative (background)
retinopathy, preproliferative (severe or advanced background)
retinopathy, and proliferative retinopathy.
The retina is comprised of several tissue types, including
neural tissue with respective support cells and vascular tissue.ALTERED ENDOTHELINS IN CHRONIC DIABETES 221
Diabetic retinopathy predominantly affects the vascular compo-
nents of the retina. Pathological changes in background diabetic
retinopathy include capillary basement membrane thickening,
pericyte loss, microaneurysms, acellular capillaries, increased
capillary permeability with exudate deposits, and retinal mi-
croinfarcts. In advanced proliferative retinopathy, neovascular-
ization develops with its devastating consequences. ETs have
demonstrated an effect on both vascular and neural tissue com-
ponents in the retina [115, 116]. Due to the multifactorial na-
ture of the pathogenesis of diabetic retinopathy, ETs can be
up-regulated and further interact with a variety of other factors
to produce pathological changes [125, 126].
Although ETs are believed to work in an autocrine and
paracrinemanner,humantype1diabeteshasdemonstratedboth
decreased[127,128]andincreased[108,114,129]plasmaET-1
levels.Patientswithtype2diabeteshavedemonstratedincreased
[109,111,130]andunchanged[131,132]plasmalevels.Positive
correlations between increased ET-1 levels and microangiopa-
thy have been demonstrated [109, 110, 133–135]. Furthermore,
plasma ET-1 levels can be returned to normal levels in the dia-
betic rats by restoring metabolic control [98].
The 2 ET isoforms expressed by the retina are ET-1 and
ET-3. In the retina, ETs have been demonstrated to localize in
theopticnerve,vascularandextravascularsitesoftheretina,and
theuvealtract[101,102,135].IncreasedmRNAandproteinex-
pressionofthe2proteinshavebeenproducedinanimaldiabetes
[102, 136, 137]. Expression of the receptor isoforms, ETA and
ETB, have demonstrated mixed results, depending upon the tis-
sue preparations. If the neural retina is isolated alone, the levels
appear to decrease and then increase [137]. If both neural and
vascular components are analyzed, then receptor levels appear
to increase [101, 136–138]. ETs can modulate the vascular tone
ofbloodvessels,dependingupontheconcentration.Atlowcon-
centrations, ETs cause vasodilation, and at high concentrations,
vasoconstriction[139–143].Thevasodilationismediatedbythe
binding of ET-1 and ET-3 to the ETB receptor. Subsequently,
through a G-protein–mediated pathway, NO or prostacyclins
are released by endothelial cells [15, 144–147]. The vasocon-
striction is mediated through ET-1 binding with ETA receptors
located on smooth muscle cells [14, 15, 147, 148]. Our own
research has demonstrated a signiﬁcant up-regulation of ET-1
and ET-3 in conjunction with increased resistivity index, in the
retina of 4-week streptozotocin (STZ)-induced diabetic animals
[101].Theresistivityindexisanindirectmeasurementofretinal
vasoconstriction.Inshort-termdiabetes,increasedresistivityin-
dex was corrected by treatment with a dual ET receptor blocker,
bosentan. However, in longer term diabetes, such vasoconstric-
tion was not present [101].
ETs possess mitogenic properties and may regulate ECM
protein synthesis [116]. Our research has illustrated that ET re-
ceptor blockade with bosentan prevents the diabetes-induced
up-regulation of basement membrane proteins, ﬁbronectin, and
collagen alpha-1 (IV) mRNA, as well as increased capillary
basement membrane thickening in both glycemic and galac-
tosemic animals [119]. Recently, we have further demonstrated
that diabetes-induced increased ECM protein production works
through NF-·B and AP-1 activation [118]. NF-·B activation
could also act as a mechanism of ET-1 up-regulation [66].
Along with the direct actions, ETs show widespread inter-
actions with other vasoactive peptides, modulating their effects
and vice versa. ET mRNA levels can be up-regulated through
theactionsofthrombin,transforminggrowthfactor-¯ (TGF-¯),
interleukin-1, epinephrine, angiotensin II, metallothionein, and
vasopressin [31, 36, 149–151]. Furthermore, we have demon-
strated a costimulatory interaction between VEGF and ETs in
cultured endothelial cells, as well as ET-1 up-regulation by NO
inhibition[42].Interestingly,intheretinasofshort-termdiabetic
animals, increases in resistivity index can be corrected with the
use of an ET blocker [101], a VEGF signal antagonist [152],
o raN a C/HC exchanger-1 (NHE-1) antagonist [91]. Although
VEGF antagonism increased iNOS mRNA expression, NHE-1
blockadereducedET-1mRNAexpressionintheseanimals[152,
153], suggesting that several interactive molecules may indeed
be responsible for the control of vascular tone in the retina.
The present data would suggest that ETs may play an impor-
tant role in the pathogenesis of diabetic retinopathy by altering
blood ﬂow, increasing vascular permeability, increasing ECM
protein synthesis, and basement membrane thickening via the
mechanisms stated above. ETs may work in conjunction with
other factors in mediating these effects. Recently, ETs have
been implicated in the pathogenesis of proliferative diabetic
retinopathy [154]. However, such role for ETs needs further
investigation.
NEPHROPATHY
Diabetic nephropathy affects approximately 30% of type 1
diabetic patients [155, 156]. Diabetes remains the most im-
portant cause of renal failure in industrialized countries [157].
Glomerular hyperﬁltration leading to microalbuminuria is the
earliest clinical marker of this disease. With progression of re-
nal damage, patients develop macroalbuminuria and reduced
glomerular ﬁltration rate [155–157].
Pathologicalfeaturesofdiabeticnephropathyincludemesan-
gial matrix expansion, thickening of glomerular capillary base-
ment membrane, and tubulointerstitial ﬁbrosis. In earlier stages,
however, there is renal enlargement due to cellular hyper-
trophy affecting both the glomeruli and tubules. Eventually,
the glomerular ﬁltration rates continue to decline and the pa-
tients develop arteriolosclerosis and glomerulosclerosis with222 S. CHAKRABARTI ET AL.
obliterationoftheﬁltrationareaduetoincreasedproductionand
decreased degradation of ECM proteins. In the later stages,
patients develop characteristic nodular accumulation of extra-
cellular matrix proteins, that is, Kimmelstiel–Wilson nodules
[157–161]. Clinically, overt nephropathy manifests as protein-
uria in the nephrotic range, hypertension, and other features
of renal failure. It has been demonstrated that, similar to other
chronic complications, a high blood glucose level is the ini-
tiating factor leading to the development of renal damage in
diabetes [162, 163]. Furthermore, it has been demonstrated that
good glucose control may even reverse the structural changes
in the kidneys [162]. Another risk factor in the progression of
nephropathyiscoexistingsystemichypertension,whichleadsto
high intraglomerular hypertension and hyperﬁltration, promot-
ing further tissue destruction and sclerosis [163].
In the kidney, both ET-1 and ET-3 show widespread tissue
distribution. ETs are expressed in the endothelium, epithelium,
mesangium, the glomeruli, the tubular epithelium, and the col-
lecting ducts and vasa recta [164, 165]. ET binding sites have
been localized in these cells and in the interstitial cells. From
a physiological perspective, ETs have roles in the regulation of
renal blood ﬂow, glomerular ﬁltration, and sodium and water
reabsorption [116, 164].
In the kidney of diabetic rats, increased ET-1 mRNA and in-
creased renal ET-1 clearance in association with proteinuria has
been demonstrated [166]. Increased ETA receptors are present
in the kidneys of diabetic rabbits [167]. Recent data from our
laboratory has demonstrated that 1 month of diabetes causes
a signiﬁcant increase in the mRNA expression of ET-1, ET-3,
ETA,E T B , which remained elevated at 6 months of follow-
up. Galactose feeding, however, resulted in increased ETA and
ETB receptor mRNA expression at 1 month, which was accom-
panied by ET-1 and ET-3 mRNA up-regulation at 6 months.
These results suggest differential activation of the components
ofETsystemindiabetesandfollowinggalactosefeeding.Never-
theless, in both animal models, glucose-induced, ET-mediated
microalbuminuria was prevented by treatment with bosentan
[165].
Thelong-termconsequencesofETpeptidesmayinvolvecel-
lular changes requiring differential gene expression and may
contribute to long-term nuclear signaling [164]. Previous stud-
ies have implicated ETs in having a regulatory link with the
components of the ECM, because rat mesangial cells showed
that ET-1 can increase the production of ECM components such
as laminin and collagen a1 (IV) [168]. Furthermore, diabetes-
inducedincreasedexpressionofglomerulara1(I),a1(III),a1(IV)
collagen, laminin B1 and B2, tumor necrosis factor-®, platelet-
derived growth factor, TGF-¯, and basic ﬁbroblast growth fac-
tor can be completely blocked by treatment with an ETA re-
ceptor antagonist [169]. We have recently demonstrated that
diabetes and galactose feeding–induced increases in ECM pro-
tein mRNA expression, glomerular basement membrane thick-
ening, and mesangial matrix expansion are prevented by bosen-
tan treatment [165]. We have further demonstrated that glucose-
induced, ET-mediated increased ECM protein ﬁbronectin syn-
thesis is mediated via transcription factors NF-·B and AP-1
[118].
Diabetic nephropathy seems to occur as a result of inter-
active metabolic factors secondary to hyperglycemia. Several
biochemical abnormalities acting secondary to hyperhexosemia
may lead to augmented ET expression in the kidneys. ETs, by
virtue of the modulation of blood ﬂow as well as ECM protein
production, are of importance in diabetic nephropathy. PKC ac-
tivation secondary to hyperglycemia may be one of the factors
up-regulating ET-1 mRNA expression. ET-1, on the other hand,
is a PKC stimulator [116, 136]. TGF-¯ in recent years has been
established as one major factor producing renal lesions in dia-
betes [161]. PKC-dependent factors, such as TGF-¯, can act as
an ET-1 stimulator and may play a signiﬁcant role in ET alter-
ation [116, 164]. It has been demonstrated that PKC¯ inhibition
results in the prevention of ECM protein synthesis and TGF-¯
production in the kidney [170]. We have previously demon-
strated that general PKC inhibition or PKC¯ inhibition prevents
the high glucose–induced increased permeability and ET-1 ex-
pression in endothelial cells [42]. ET-mediated increased ECM
protein production may represent one of the long-term effects
of ET-1, possibly mediated via several kinases, including PKC,
MAP kinase, and serine/threonine kinase, and transcription fac-
tors, which warrant further investigations [115].
NEUROPATHY
Both the somatic and autonomic nervous system can be af-
fected by diabetes, causing a variety of symptoms. Diabetes is a
majorcauseofperipheralneuropathyinthewesternworld[171].
A signiﬁcant number (60% to 70%) of diabetic patients show
variable degrees of nerve damage. At the severe end of the spec-
trum, diabetic nerve disease is a major cause of lower extremity
amputation [162]. Broadly, diabetic neuropathy can be classi-
ﬁed as mononeuropathies or polyneuropathies. The mononeu-
ropathies may affect peripheral or cranial nerves and can in-
volve single nerves or may affect multiple nerves (mononeuritis
multiplex) [171, 172]. Sensory, motor, or autonomic nervous
systems may be affected by polyneuropathies. Chronic sensori-
motor polyneuropathy is the most common type of neuropathy.
It is manifested as progressive gloves and stocking anesthesia,
paresthesia,orhyperasthesia,impairedbalance,proprioception,
and vibration. Although motor weakness is not pronounced,
wasting of small muscle and loss of reﬂex activity are mani-
fested. Foot ulceration and other neuropathic changes may sub-
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electrophysiological feature of diabetic neuropathy. Autonomic
neuropathy may produce gastrointestinal or urological motil-
ity problems and postural hypotension [171, 172]. Acute sen-
sory neuropathy, although a painful condition, usually leads to
completerecovery.Proximalmotorneuropathies,alsoknownas
amyotrophy,aremanifestedasacuteonsetofpainandweakness
of proximal muscles.
Impaired activity of PKC and NaC,KC-ATPase as a result
of reduced phosphoinositide metabolism in the peripheral nerve
hasbeendemonstratedindiabetes[173].Thisisinsharpcontrast
to the retinal ﬁndings where activation of PKC has been estab-
lished [43, 44]. These data indicate that pathogenetic pathways
may be inﬂuenced by the tissue microenvironment in hyper-
glycemia and may vary in target organs of diabetic complica-
tions. Although peripheral nerves from diabetic animals show
reduced DAG levels [173–175], PKC inhibitors prevent
diabetes-induced reduced neuronal NaC,KC-ATPase activity
[176]. It is possible that impaired phosphoinositide metabolism,
in the peripheral nerves in diabetes, may inﬂuence ET-mediated
signal transduction [177]. In addition, reduced NO production,
as demonstrated in the vasculature of the peripheral nerve in
diabetes, may also lead to increased ET synthesis [178]. How-
ever, these notions need conﬁrmation by speciﬁc experiments.
Reduced endoneurial blood ﬂow and nerve conduction veloc-
ity deﬁcit in the STZ-induced diabetic rats were prevented by a
speciﬁc ETA antagonist and by blockade of both ETA and ETB
receptors [104, 179]. We have demonstrated that immunoreac-
tivity of ET-1 and ET-3 is increased in the peripheral nerve in
diabetes [180]. The predominant effect of ET-1 in neuropathy
maybemediatedviathevascularconsequences.Recently,ithas
further been shown that susceptibility to ET-induced multifocal
ischemic damage of the peripheral nerves in diabetic animals is
much greater compared to nondiabetic animals [181]. No data,
however, are yet available that demonstrate the effects of ET
blockade on later changes in diabetic neuropathy such as nerve
ﬁber loss.
MACROANGIOPATHY
Among the diabetic complications, macroangiopathy is the
major cause of mortality in diabetic patients. Type 2 dia-
betes mellitus is one independent risk factor for atherosclerosis
along with hyperlipidemia, hypertension, and smoking. Coro-
nary atherosclerosis leading to myocardial infarction is a lead-
ingcauseofdeathinthediabeticpopulation[182].Intype1and
type2diabeticpatients,carotidstenosissecondarytoanincrease
intimal and medial wall thickness has been associated with an
increased risk of stroke. Furthermore, a direct relationship be-
tween carotid artery wall thickness and blood glucose levels in
diabetic patients has been noted [183]. Lower extremity arterial
disease (LEAD) has been considered to be among the major
indications for amputation in individuals with type 1 and type 2
diabetes. The progression of LEAD in diabetes is compounded
by such comorbidity as peripheral neuropathy and insensitivity
of the feet and lower extremities to pain and trauma [184].
AlterationsoftheplasmaET-1levelshavebeendemonstrated
in several diseases associated with endothelial dysfunction, that
is, diabetes, hypertension, and atherosclerosis [185]. ET-1 is re-
leasedbyendothelialcellsandcausesphenotypicmodulationof
the vascular smooth muscle cells from contractile type to syn-
thetictype[186].ET-1alsocausesintimalvasodilationbyactiva-
tionofETB receptorsonendothelialcells[187].Inadditiontoits
vasoconstrictorproperties,ET-1isapotentmitogenandinduces
vascularsmoothmusclecellproliferationandmedialthickening.
The importance of ET-1 in diabetes-associated vascular hyper-
trophy was initially suggested by studies reporting an increased
release of this peptide from mesenteric vessels in diabetic rats
[188], as well as in type 2 diabetic patients with atheroscle-
rotic macro- and microvascular diseases [189]. Recent studies
have demonstrated increased ET-1 expression in the endothe-
lium, adventitia, and the media of diabetic mesenteric vessels in
rats [190] and in type 2 diabetic patients with macroangiopathy
[191]. High levels of plasma ET-1 were also demonstrated in
type 2 diabetic patients with atherosclerosis [134].
Although the expression of prepro ET-1 mRNA was signiﬁ-
cantly enhanced in aortas from STZ-induced diabetic rats, some
investigators demonstrated that the contractile response of the
aorta to ET-1 was weaker in STZ-induced diabetic rats than in
nondiabetic controls, in association with a down-regulation of
ET receptors. Impaired ET-induced signal transduction mech-
anisms are suggested to be present in these animals [192]. In
addition to the direct effect of ETs, there are several interac-
tions between various neurohormonal pathways, including the
renin-angiotensin system and ET. In a nondiabetic model, it has
been demonstrated that angiotensin II–induced vascular hyper-
trophy can be attenuated by ET receptor antagonism [193, 194].
ETs may also have roles in mediating increased noradrenaline-
mediated vasoconstriction in the aorta and mesenteric vessels
of diabetic rats [94]. Furthermore, hyperinsulinemia in the con-
text of insulin resistance may further augment ET-1 action, as
insulin is a stimulator of ET-1 production, leading to further
smooth muscle proliferation [116, 164]. The present data sug-
gest that ETs may play an important role in the pathogenesis
of diabetic macroangiopathy by inﬂuencing smooth muscle cell
phenotype and functional properties. Further well-designed ex-
perimental and clinical investigations are necessary to establish
the exact mechanisms.
CARDIOMYOPATHY
Cardiac affection in diabetes may occur due to the conse-
quences of coronary artery disease, autonomic neuropathy, and224 S. CHAKRABARTI ET AL.
diabetic cardiomyopathy, either alone or in combination. Pri-
mary affection of cardiomyocytes in diabetes, that is, diabetic
cardiomyopathy, can act as an independent factor affecting the
cardiac structure and function and may also modulate progno-
sis of other complications such as ischemic heart disease [195,
196]. It was demonstrated that diabetic patients had larger mean
diameters of ventricular myocardial cells and higher percent-
age of interstitial ﬁbrosis than control subjects. Morphological
changes in diabetic cardiomyopathy include myocyte hypertro-
phy and/or necrosis, interstitial and perivascular ﬁbrosis, and
capillarybasementmembranethickening[196,197].Functional
abnormalities involve both the systolic and diastolic properties
of the myocardium, such as impaired relaxation, reduced com-
pliance with elevated end-diastolic pressure, cardiac hypertro-
phy, and chamber dilatation [197, 198].
ETs play important roles in several cardiovascular diseases,
including diabetic cardiomyopathy, by modulating functional
properties of cardiomyocytes and the microvasculature [100].
In the heart, both cardiomyocytes and endothelial cells pro-
duce ET-1. Cardiac myocytes have high ET-1 binding afﬁnity
sites [199–202]. ET-1 produces pronounced positive inotropic
and chronotropic effects on the heart [197–204]. A duration-
dependent alteration of chronotropic and inotropic responses
of ET-1 was demonstrated in the isolated atria of the diabetic
rat [205]. Short-term hyperglycemia increased the expression
of prepro ET-1 in the heart of STZ-diabetic rats [206–209]. We
have demonstrated a signiﬁcant up-regulation of ET-1 and ETA
and ETB receptor mRNA expression, as well as increased ET
immunoreactivity and ET receptor density in hearts of 6-month
diabetic rats [100]. These changes were associated with focal
apoptosis of cardiomyocytes, scarring of the myocardium, and
increased ﬁbronectin and collagen a1(IV) mRNA expression.
Furthermore, such diabetes-induced abnormalities were com-
pletely prevented by bosentan [100]. In humans, high plasma
levels of ET-1 is thought to play an important role in the patho-
genesisofdiastolicdysfunctionindiabeticpatientswithcardiac
autonomic neuropathy [207] . It has been further demonstrated
that reperfusion following cardioplegia during coronary artery
bypass grafting procedure can trigger the release of ET-1 in dia-
betic patients [208], which may further contribute to signiﬁcant
cardiovascular demise in diabetic patients.
SomeoftheeffectsofET-1ontheheartandvasculaturecould
be partially mediated via activation of NHE-1, the major proton
pump mechanism in the heart, through the IP3-DAG pathway
[209, 210]. We have demonstrated that both ET-1 and NHE-1
play important roles in the pathogenesis of diabetic heart dis-
ease. NHE-1 may act as the downstream mediator in the de-
velopment of ET-mediated functional and structural changes
in diabetic myocardium [211]. PKC activation may be one of
thepathwaysleadingtoETup-regulationintheheartindiabetes
[43,44,50].However,severalotherfactorsmayalsobeinvolved
in the up-regulation of ET-1 expression in diabetes. ET-1 inter-
acts with other potent vasoactive substances, such as NO and
VEGF [211–214]. Increased VEGF in diabetes may also lead
to increased ET-1 expression [42]. On the other hand, nonen-
zymatic glycation and oxidative stress reduces NO production
in diabetes, which in turn increases ET-1 expression [79]. We
have recently demonstrated that diabetes-induced reduction in
NOS expression and NO activity in the heart may be corrected
by treatment with bosentan [215].
CONCLUSION
Evidence gathered so far indicates that pathogenetic mech-
anisms leading to chronic diabetic complications are complex.
Several factors may be simultaneously activated in response to
hyperglycemia, and an intricate interplay occurs among such
factors. Furthermore, tissue-speciﬁc variations exist due to the
inﬂuence of the tissue microenvironment. This concept further
explains prevention and/or delay of chronic diabetic complica-
tions with good blood glucose control and failure of adjuvant
treatments that block a single pathway, such as aldose reduc-
tase inhibition in clinical trials [216, 217]. ETs, due to their
widespread tissue distribution, multiple functional capabilities,
andalterationinthetargetorgansofdiabeticcomplications,may
play signiﬁcant roles as effector molecules in chronic diabetic
complications. Abnormal metabolic pathways secondary to hy-
perglycemia, such as PKC activation, nonenzymatic glycation,
oxidative damage, as well as augmented polyol pathway may,
in part, directly or indirectly contribute to the alteration of ETs.
ETs may further affect activity of other vasoactive factors. Ev-
idences gathered from multiple animal experiments in several
laboratories,indeed,indicatethatETsareimportantinthepatho-
genesis of several chronic diabetic complications. ET antago-
nism may be a potential therapeutic modality in the treatment of
chronic diabetic complications, such as retinopathy, nephropa-
thy, neuropathy, and cardiovascular complications. These data,
however, have to be further conﬁrmed by additional long-term
studies in experimental animals as well as by thorough well-
designed clinical trials.
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